Free Trial

Weiss Ratings Reaffirms Hold (C-) Rating for Elevance Health (NYSE:ELV)

Elevance Health logo with Medical background

Key Points

  • Weiss Ratings has reaffirmed its "hold (C-)" rating for Elevance Health (NYSE:ELV), reflecting a cautious outlook on the stock.
  • Analysts have varied price objectives for Elevance Health, with estimates ranging from $297.00 to $398.00, indicating mixed sentiment among investment firms.
  • Elevance Health reported a quarterly earnings per share (EPS) of $6.03, surpassing estimates and showing a 12% revenue increase from the previous year.
  • Interested in Elevance Health? Here are five stocks we like better.

Elevance Health (NYSE:ELV - Get Free Report)'s stock had its "hold (c-)" rating restated by investment analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

ELV has been the topic of a number of other reports. Leerink Partners reaffirmed a "market perform" rating and set a $310.00 price objective (down from $510.00) on shares of Elevance Health in a research report on Friday, July 18th. Robert W. Baird lowered their price objective on Elevance Health from $492.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Guggenheim lifted their price objective on Elevance Health from $360.00 to $398.00 and gave the company a "buy" rating in a research report on Wednesday, October 8th. Truist Financial set a $400.00 price objective on Elevance Health in a research report on Tuesday, October 14th. Finally, UBS Group lowered their price objective on Elevance Health from $435.00 to $425.00 and set a "buy" rating on the stock in a research report on Friday, September 5th. Twelve equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $397.89.

Get Our Latest Analysis on Elevance Health

Elevance Health Trading Down 1.1%

Elevance Health stock opened at $342.45 on Friday. The business has a 50-day simple moving average of $327.09 and a two-hundred day simple moving average of $353.39. The company has a market cap of $76.11 billion, a P/E ratio of 14.00, a P/E/G ratio of 1.26 and a beta of 0.59. Elevance Health has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a quick ratio of 1.44, a current ratio of 1.56 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.03 by $1.00. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The business had revenue of $50.09 billion during the quarter, compared to the consensus estimate of $49.26 billion. During the same period in the previous year, the company posted $8.37 EPS. The business's quarterly revenue was up 12.0% compared to the same quarter last year. Analysts predict that Elevance Health will post 33.96 EPS for the current year.

Insider Buying and Selling

In other Elevance Health news, Director Susan D. Devore purchased 1,200 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were bought at an average cost of $312.15 per share, with a total value of $374,580.00. Following the acquisition, the director owned 3,502 shares in the company, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.29% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Verdence Capital Advisors LLC lifted its holdings in Elevance Health by 3.9% in the 2nd quarter. Verdence Capital Advisors LLC now owns 21,213 shares of the company's stock worth $8,251,000 after purchasing an additional 790 shares in the last quarter. Dynamic Advisor Solutions LLC increased its stake in Elevance Health by 11.3% in the 2nd quarter. Dynamic Advisor Solutions LLC now owns 8,034 shares of the company's stock worth $3,125,000 after acquiring an additional 817 shares during the last quarter. Focus Partners Wealth increased its stake in Elevance Health by 4.6% in the 1st quarter. Focus Partners Wealth now owns 22,446 shares of the company's stock worth $9,764,000 after acquiring an additional 982 shares during the last quarter. Asio Capital LLC increased its stake in Elevance Health by 7.1% in the 2nd quarter. Asio Capital LLC now owns 15,371 shares of the company's stock worth $5,979,000 after acquiring an additional 1,015 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Elevance Health by 88.1% in the 1st quarter. GAMMA Investing LLC now owns 3,390 shares of the company's stock worth $1,475,000 after acquiring an additional 1,588 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

About Elevance Health

(Get Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Further Reading

Analyst Recommendations for Elevance Health (NYSE:ELV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elevance Health Right Now?

Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.